Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Accumulated Expenses (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Accumulated Expenses for 14 consecutive years, with $40.2 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 1.99% to $40.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $40.2 million through Dec 2025, up 1.99% year-over-year, with the annual reading at $3.1 million for FY2025, 91.79% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $40.2 million at Aytu Biopharma, up from $36.7 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $54.4 million in Q3 2021, with the low at $3.1 million in Q2 2025.
  • Average Accumulated Expenses over 5 years is $31.3 million, with a median of $39.4 million recorded in 2024.
  • The sharpest move saw Accumulated Expenses skyrocketed 2664.57% in 2021, then tumbled 92.15% in 2024.
  • Over 5 years, Accumulated Expenses stood at $50.7 million in 2021, then tumbled by 91.89% to $4.1 million in 2022, then surged by 956.28% to $43.4 million in 2023, then dropped by 9.31% to $39.4 million in 2024, then rose by 1.99% to $40.2 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $40.2 million, $36.7 million, and $3.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.